A study on the efficacy and biogenic adaptability affected by ipragliflozin - A study on the efficacy and biogenic adaptability affected by ipragliflozin

Kobe University0 sites104 target enrollmentJuly 1, 2015

Overview

After SGLT2 inhibitor adoministration, appetite of participants increased, and the level of plasma leptin levels increased.

Registry

who.int

Start Date

July 1, 2015

End Date

November 16, 2017

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\) Type 1 diabetes 2\) With severe ketosis, diabetic coma, or precoma within 6 months 3\) With severe infection, pre or post surgery, and serious trauma 4\) With severe hepatic dysfunction 5\) With renal dysfunction (Serum Creatinine male: \>\= 1\.5 mg/dL, female: \>\= 1\.3 mg/dL) 6\) Is receiving steroids 7\) Has history of gastrectomy (include segmentectomy and total resection, but not endoscopic mucosal resection) 8\) Has stroke, myocardial infarction, or other serious cardiovascular complications requiring hospitalization within 6 months at consent 9\) Has history of receiving SGLT\-2 inhibitor 10\) Is pregnant, nursing, or planned to become pregnant 11\) Has history of hypersensitivity to ipragliflozin or any other excipient of ipragliflozin 12\) Considered as inadequate by the investigator